CAS 313-67-7|Aristolochic acid A
| Common Name | Aristolochic acid A | ||
|---|---|---|---|
| CAS Number | 313-67-7 | Molecular Weight | 341.27 |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 615.5±55.0 °C at 760 mmHg |
| Molecular Formula | C17H11NO7 | Melting Point | 260 °C |
| MSDS | ChineseUSA | Flash Point | 326.0±31.5 °C |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | aristolochic acid |
|---|---|
| Synonym | More Synonyms |
Aristolochic acid A BiologicalActivity
| Description | Aristolochic acid A (Aristolochic acid I) is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. AAI significantly reduces both activator protein 1 (AP-1) and NF-κB activities. Aristolochic acid A reduces BLCAP gene expression in human cell lines[1]. |
|---|---|
| Related Catalog | Research Areas >>Cancer |
| In Vitro | Aristolochic acid A (150, 200 μM, 24 hours) inhibits the cell viabilities of kidney cells HEK293 and HK-2[1]. Aristolochic acid A (100, 200 μM, 24 hours) causes a concentration-dependent decrease in bladder cancer-associated protein (BLCAP) mRNA levels in kidney cells (HEK 293 and HK-2) , and bladder cancer cell line (HT-1376)[1]. Aristolochic acid A (100, 200 μM, 24 hours) weakens the BLCAP protein signals in a dose-dependent manner in both HEK293 and HT-1376 cells[1]. Cell Viability Assay[1] Cell Line: Kidney cells (HEK 293 and HK-2) Concentration: 50, 100, 150, 200 μM Incubation Time: 24 hours Result: The cell viabilities of HEK293 and HK-2 were lower than that of vehicle-treated cultures until 150 μM and 200 μM. RT-PCR[1] Cell Line: Kidney cells (HEK 293 and HK-2), and bladder cancer cell line (HT-1376) Concentration: 100, 200 μM Incubation Time: 24 hours Result: Down regulated the levels of BLCAP mRNA. Western Blot Analysis[1] Cell Line: HEK293 and HT-1376 cells Concentration: 100, 200 μM Incubation Time: 24 hours Result: Reduced the BLCAP protein expression in a dose-dependent manner. |
| References | [1]. Huang YT, et al. Aristolochic acid I interferes with the expression of BLCAP tumor suppressor gene in human cells. Toxicol Lett. 2018 Jul;291:129-137. |
Chemical & Physical Properties
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 615.5±55.0 °C at 760 mmHg |
| Melting Point | 260 °C |
| Molecular Formula | C17H11NO7 |
| Molecular Weight | 341.27 |
| Flash Point | 326.0±31.5 °C |
| Exact Mass | 341.053558 |
| PSA | 110.81000 |
| LogP | 3.41 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.747 |
| Water Solubility | DMSO: soluble |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 3 mg/kg/2D-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 184 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 74 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 55900 ug/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 14320 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 38400 ug/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - cat
- DOSE/DURATION :
- 40 mg/kg
- TOXIC EFFECTS :
- Vascular - BP elevation not characterized in autonomic section Lungs, Thorax, or Respiration - respiratory depression Lungs, Thorax, or Respiration - respiratory stimulation
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 1500 ug/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - muscle weakness Nutritional and Gross Metabolic - weight loss or decreased weight gain
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 22 mg/kg/11D-I
- TOXIC EFFECTS :
- Blood - changes in other cell count (unspecified) Skin and Appendages - dermatitis, other (after systemic exposure)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 105 mg/kg/3W-C
- TOXIC EFFECTS :
- Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Gastrointestinal - tumors
- TYPE OF TEST :
- Sex chromosome loss and nondisjunction
- TYPE OF TEST :
- DNA adduct
- TYPE OF TEST :
- Mutation in mammalian somatic cells
- TYPE OF TEST :
- Mutation in mammalian somatic cells
MUTATION DATA - TYPE OF TEST :
- Mutation in mammalian somatic cells
- TEST SYSTEM :
- Rodent - hamster Ovary
- DOSE/DURATION :
- 50 umol/L
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 206,447,1988
- TYPE OF TEST :
- Mutation in mammalian somatic cells
- TEST SYSTEM :
- Rodent - hamster Ovary
- DOSE/DURATION :
- 50 umol/L
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 206,447,1988
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T:Toxic |
| Risk Phrases | R25 |
| Safety Phrases | S7-S35-S45 |
| RIDADR | UN 1544 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | CF3325000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
Articles39
More Articles| Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. Toxicology 318 , 22-31, (2014) Bardoxolone methyl (BARD) is an antioxidant modulator that acts through induction of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway. This study aimed to investigate the role ... | |
| Baicalin Protects Mice from Aristolochic Acid I-Induced Kidney Injury by Induction of CYP1A through the Aromatic Hydrocarbon Receptor. Int. J. Mol. Sci. 16 , 16454-68, (2015) Exposure to aristolochic acid I (AAI) can lead to aristolochic acid nephropathy (AAN), Balkan endemic nephropathy (BEN) and urothelial cancer. The induction of hepatic CYP1A, especially CYP1A2, was co... | |
| Association of blood lead and mercury with estimated GFR in herbalists after the ban of herbs containing aristolochic acids in Taiwan. Occup. Environ. Med. 70(8) , 545-51, (2013) This study was undertaken to explore the association of estimated glomerular filtration rate (GFR) with exposure to aristolochic acids (ALAs) and nephrotoxic metals in herbalists after the ban of herb... |
Synonyms
| Aristolohic Acid A |
| Descresept |
| 8-methoxy-3,4-methylenedioxy-10-nitrophenanthrene-1-carboxylic acid |
| Aristolochic acid |
| birthwort |
| Phenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro- |
| AristolochicacidI |
| EINECS 206-238-3 |
| Aristolochia |
| tardolyt |
| Aristolochic Acid A |
| Aristolochia A |
| aristolochin |
| 8-Methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid |
| TR 1736 |
| Aristolochic |
| MFCD00004996 |
| aristolochine |
| 8-Methoxy-6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic Acid |
